자동화 및 폐쇄형 세포 치료 공정 시스템 시장 규모, 점유율 및 동향 분석 보고서 : 워크플로우별, 유형별, 규모별, 지역별, 부문별 예측(2026-2033년)

Automated And Closed Cell Therapy Processing Systems Market Summary

The global automated and closed cell therapy processing systems market size was estimated at USD 1.67 billion in 2025 and is projected to reach USD 7.44 billion by 2033, growing at a CAGR of 20.73% from 2026 to 2033. The growing popularity of regenerative medicine & cell therapies, coupled with a range of benefits offered by automation technologies for developing these therapies, is expected to propel market growth.

In addition, the growing integration of software technologies and advanced therapy development processes is expected to drive market growth. Rising investments by bio manufacturers for developing cellular therapy products through rounds of series funding are anticipated to offer lucrative growth opportunities. Moreover, the increasing demand for scalable, safe, and contamination-free cell therapy manufacturing solutions, highlighted by innovations such as animal origin-free formulations, is driving the market's growth.

Growing Cell & Gene Therapy Pipeline Driving Manufacturing Demand

The expanding pipeline of cell and gene therapies, including CAR-T, NK, TCR-based, and emerging allogeneic modalities, is significantly increasing the need for scalable, high-throughput manufacturing systems. As more programs advance into clinical development, developers are experiencing rising pressure to enhance production capacity while maintaining strict quality and regulatory standards. This growth is also accompanied by an increasing number of autologous therapies, each requiring individualized processing, which further amplifies the strain on manual and semi-automated workflows.

With multiple late-stage cell therapy candidates moving closer to commercialization, manufacturers are prioritizing automated and closed systems to support larger batch volumes, greater operational efficiency, and stronger contamination control. Traditional manual processes are proving insufficient for meeting accelerated timelines, reproducibility expectations, and the higher throughput required as the market expands. Automated platforms that integrate cell isolation, activation, expansion, and formulation steps are becoming essential for reducing cycle times and ensuring consistent product quality.

In addition, the shift toward allogeneic, "off-the-shelf" cell therapies is reshaping production strategies and driving demand for systems that can support true industrial-scale manufacturing. These therapies rely on repeatable, high-yield processes that automated and closed platforms are better equipped to deliver. Collectively, the broadening therapeutic pipeline is prompting companies to invest heavily in next-generation manufacturing technologies to ensure scalability, efficiency, and sustained competitiveness in a rapidly evolving market.

Global Automated and Closed Cell Therapy Processing Systems Market Report Segmentation

This report forecasts revenue growth at global, regional and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global automated and closed cell therapy processing systems market report based on workflow, type, scale, and region:

• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Separation
• Expansion
• Apheresis
• Fill- Finish
• Cryopreservation
• Others
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Stem Cell Therapy
• Non Stem Cell Therapy
• Scale Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-Commercial/ R&D Scale
• Commercial Scale
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Workflow
  • 1.2.2. Type
  • 1.2.3. Scale
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Automated and Closed Cell Therapy Processing Systems Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  • 3.3.2. PESTLE Analysis

Chapter 4. Automated and Closed Cell Therapy Processing Systems Market: Workflow Business Analysis

• 4.1. Workflow Market Share, 2025 & 2033
• 4.2. Workflow Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
• 4.4. Separation
  • 4.4.1. Separation market, 2021 - 2033 (USD Million)
• 4.5. Expansion
  • 4.5.1. Expansion market, 2021 - 2033 (USD Million)
• 4.6. Apheresis
  • 4.6.1. Apheresis market, 2021 - 2033 (USD Million)
• 4.7. Fill- Finish
  • 4.7.1. Fill- Finish market, 2021 - 2033 (USD Million)
• 4.8. Cryopreservation
  • 4.8.1. Cryopreservation market, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others market, 2021 - 2033 (USD Million)

Chapter 5. Automated and Closed Cell Therapy Processing Systems Market: Type Business Analysis

• 5.1. Type Market Share, 2025 & 2033
• 5.2. Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 5.4. Stem Cell Therapy
  • 5.4.1. Stem cell therapy market, 2021 - 2033 (USD Million)
• 5.5. Non Stem Cell Therapy
  • 5.5.1. Non stem cell therapy market, 2021 - 2033 (USD Million)

Chapter 6. Automated and Closed Cell Therapy Processing Systems Market: Scale Business Analysis

• 6.1. Scale Market Share, 2025 & 2033
• 6.2. Scale Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Scale, 2021 to 2033 (USD Million)
• 6.4. Pre-Commercial/ R&D Scale
  • 6.4.1. Pre-commercial/ R&D scale market, 2021 - 2033 (USD Million)
• 6.5. Commercial Scale
  • 6.5.1. Commercial scale market, 2021 - 2033 (USD Million)

Chapter 7. Automated and Closed Cell Therapy Processing Systems Market: Regional Estimates & Trend Analysis by Workflow, Type, and Scale

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamic
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive insights
    • 7.4.2.4. U.S. automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamic
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive insights
    • 7.4.3.4. Canada automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamic
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive insights
    • 7.4.4.4. Mexico automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamic
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive insights
    • 7.5.2.4. UK automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamic
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive insights
    • 7.5.3.4. Germany automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamic
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive insights
    • 7.5.4.4. France automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamic
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive insights
    • 7.5.5.4. Italy automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamic
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive insights
    • 7.5.6.4. Spain automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key country dynamic
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive insights
    • 7.5.7.4. Denmark automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamic
    • 7.5.8.2. Regulatory framework
    • 7.5.8.3. Competitive insights
    • 7.5.8.4. Sweden automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key country dynamic
    • 7.5.9.2. Regulatory framework
    • 7.5.9.3. Competitive insights
    • 7.5.9.4. Norway automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamic
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive insights
    • 7.6.2.4. Japan automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamic
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive insights
    • 7.6.3.4. China automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamic
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive insights
    • 7.6.4.4. India automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamic
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive insights
    • 7.6.5.4. Australia automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamic
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive insights
    • 7.6.6.4. Thailand automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. South Korea
    • 7.6.7.1. Key country dynamic
    • 7.6.7.2. Regulatory framework
    • 7.6.7.3. Competitive insights
    • 7.6.7.4. South Korea automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamic
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive insights
    • 7.7.2.4. Brazil automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamic
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive insights
    • 7.7.3.4. Argentina automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamic
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive insights
    • 7.8.2.4. South Africa automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamic
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive insights
    • 7.8.3.4. Saudi Arabia automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamic
    • 7.8.4.2. Regulatory framework
    • 7.8.4.3. Competitive insights
    • 7.8.4.4. UAE automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamic
    • 7.8.5.2. Regulatory framework
    • 7.8.5.3. Competitive insights
    • 7.8.5.4. Kuwait automated and closed cell therapy processing systems market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Miltenyi Biotec
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. Lonza
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. Fresenius Kabi AG
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. Danaher Corporation
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. BioSpherix, LLC
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. Terumo Corporation
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. Sartorius AG
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. ThermoGenesis Holdings, Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. CELLARES
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. Thermo Fisher Scientific Inc.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product benchmarking
    • 8.5.10.4. Strategic initiatives